Holen Sie sich die Stockscreener-App
22.32
0.54%
0.12
Handel nachbörslich:
22.76
0.44
+1.97%
Schlusskurs vom Vortag:
$22.20
Offen:
$21.99
24-Stunden-Volumen:
1.29M
Relative Volume:
0.80
Marktkapitalisierung:
$3.81B
Einnahmen:
$1.07B
Nettoeinkommen (Verlust:
$391.00M
KGV:
9.7535
EPS:
2.2884
Netto-Cashflow:
$6.31M
1W Leistung:
+5.93%
1M Leistung:
+0.72%
6M Leistung:
+3.38%
1J Leistung:
+45.12%
1-Tages-Spanne:
$21.99
$22.74
1-Wochen-Bereich:
$21.26
$22.89
52-Wochen-Spanne:
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.32 | 3.78B | 1.07B | 391.00M | 6.31M | 2.2884 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-23 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
IPO Launch: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Growth vs Value & Technical Confirmation Alerts - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Trade Near Recent Levels - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
ACAD PE Ratio & Valuation, Is ACAD Overvalued - Intellectia AI
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII.com
Insiders At ACADIA Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - 富途牛牛
ACADIA Pharmaceuticals Inc (DR6.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Glioblastoma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic Therapeuti - Barchart
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
Layoff Watch: Is ACADIA Pharmaceuticals Inc being accumulated by smart moneyStop Loss & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Update Recap: Can ACADIA Pharmaceuticals Inc continue delivering strong returns - baoquankhu1.vn
Acadia Pharmaceuticals stock drops 3.35% as company gears up for post-acute care conference - Traders Union
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance - simplywall.st
Acadia Pharma EVP Schneyer sells $159k in stock By Investing.com - au.investing.com
Acadia Pharma EVP Schneyer sells $159k in stock - Investing.com UK
Acadia Pharmaceuticals exec sells $41,895 in stock By Investing.com - Investing.com India
Acadia Pharmaceuticals exec sells $41,895 in stock - Investing.com
Acadia EVP Thompson sells $73k in stock after option exercise - Investing.com
Acadia EVP Rhodes sells $82k in stock after option exercise - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock By Investing.com - Investing.com India
Acadia EVP Rhodes sells $82k in stock after option exercise By Investing.com - za.investing.com
ACADIA (NASDAQ: ACAD) officer sells 1,942 shares after RSU vesting - Stock Titan
ACADIA Pharmaceuticals (NASDAQ: ACAD) — Vanguard reports 0 shares in amendment - Stock Titan
Acadia Pharmaceuticals stock price forecast: overbought conditions persist as ACAD closes near key resistance - Traders Union
This General Motors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
ACADIA Pharmaceuticals Shares Rise After BofA Upgrade - Moomoo
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Upgraded to Buy by BofA - gurufocus.com
Acadia Pharma upgraded at BofA following stock pullback - msn.com
Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback - TipRanks
ACAD: B of A Securities Upgrades ACADIA Pharmaceuticals Rating t - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Raised to "Buy" at Bank of America - MarketBeat
BofA upgrades Acadia Pharmaceuticals stock rating on valuation - Investing.com
RBC Capital Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
BofA upgrades Acadia Pharmaceuticals stock rating on valuation By Investing.com - Investing.com Canada
B of A Securities upgrades ACADIA Pharmaceuticals (ACAD) - MSN
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Hudson Bay Capital Management LP Sells 119,700 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Market Recap: How does ACADIA Pharmaceuticals Inc compare to its peersBreakout Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
Hedge Fund Moves: How does ACADIA Pharmaceuticals Inc compare to its peersProfit Target & Long-Term Safe Investment Plans - baoquankhu1.vn
Aug Outlook: Does ACADIA Pharmaceuticals Inc offer margin of safety2026 Analyst Calls & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Acadia (NASDAQ: ACAD) director receives new option and RSU awards - Stock Titan
ACADIA (NASDAQ: ACAD) director Jonathan Poole submits initial Form 3 insider report - Stock Titan
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - msn.com
Mizuho upgrades ACADIA Pharmaceuticals (ACAD) - MSN
Oppenheimer maintains a balanced outlook on ACADIA Pharmaceuticals Inc. (ACAD) for 2026 - MSN
Wolfe Research notes conviction-driven opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) therapeutic domains - MSN
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acadia Pharmaceuticals Inc-Aktie (ACAD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Owen Adams Catherine | Chief Executive Officer |
Mar 25 '26 |
Sale |
21.47 |
11,641 |
249,932 |
14,803 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC |
Mar 24 '26 |
Option Exercise |
0.00 |
7,515 |
0 |
15,124 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC |
Mar 25 '26 |
Sale |
21.47 |
3,844 |
82,531 |
11,280 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev |
Mar 25 '26 |
Sale |
21.47 |
3,435 |
73,749 |
3,280 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
Mar 26 '26 |
Sale |
21.65 |
1,109 |
24,011 |
26,885 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
Mar 25 '26 |
Sale |
21.47 |
833 |
17,885 |
25,852 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Mar 25 '26 |
Sale |
21.47 |
4,177 |
89,680 |
57,299 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Mar 26 '26 |
Sale |
21.65 |
3,208 |
69,456 |
60,269 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC |
Feb 06 '26 |
Option Exercise |
0.00 |
12,944 |
0 |
14,559 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC |
Feb 09 '26 |
Sale |
23.38 |
6,950 |
162,491 |
7,609 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):